{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00029256", "CSN": null, "TRF": "ORD_1624876_01", "MRN": "49354087", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1318282", "clinicalId": "1319629", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1624876_01", "SampleName": "US1550561.01", "Version": "0", "Sample": {"FM_Id": "ORD_1624876_01", "SampleId": "US1550561.01", "BlockId": "nan", "TRFNumber": "ORD_1624876_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2023_05_08", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10105", "MRN": "49354087", "FullName": "\u8463\u6dd1\u5a23", "FirstName": "Shu_Ti", "LastName": "Tung", "SubmittedDiagnosis": "Pancreas adenosquamous carcinoma", "Gender": "Female", "DOB": "1949_02_28", "OrderingMD": "\u8a31\u52ad\u69ae", "OrderingMDId": "109266", "Pathologist": "\u676d\u4ec1\u91e9", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2023_05_04", "ReceivedDate": "2023-05-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "4", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "AR", "isVUS": "true", "variantName": "S176R"}, {"geneName": "ATM", "isVUS": "true", "variantName": "S2489F"}, {"geneName": "CD79B", "isVUS": "true", "variantName": "N73T"}, {"geneName": "CUL4A", "isVUS": "true", "variantName": "I404V"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "T39M"}, {"geneName": "FGFR3", "isVUS": "true", "variantName": "R248H"}, {"geneName": "MEF2B", "isVUS": "true", "variantName": "P203L"}, {"geneName": "PDCD1LG2 (PD_L2)", "isVUS": "true", "variantName": "D111N"}, {"geneName": "PIK3C2B", "isVUS": "true", "variantName": "P798S"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "T672M"}, {"geneName": "RET", "isVUS": "true", "variantName": "A249fs*6"}, {"geneName": "VHL", "isVUS": "true", "variantName": "V62M"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "Q61H", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.96", "isEquivocal": "false", "name": "Q61H"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, K117R, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 91_95% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536), with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS_mutated, PD_L1 positive disease (Zhu et al., 2022; 35240087). Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS_mutated pancreatic tumors (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine experienced a PR (Kinsey et al., 2019; 30833748). A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479). A Phase 1b study of second_line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10) (Mahalingham et al., 2020;31694832); an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin (Noonan et al., 2016; 27039845). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events for patients with KRAS_mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), despite promising results in earlier trials of MEK inhibitor monotherapies (Bodoky et al., 2012; 21594619, Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733, Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated LGSOC and 12% (2/17) for patients with KRAS_mutated NSCLC in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical studies suggest that KRAS activating mutations may confer sensitivity to SOS1 inhibitors such as BI_3406, MRTX0902, BI_1701963, and BAY_293 as single agents (Hofmann et al., 2021; 32816843, He et al., 2022; 36173339, Zhang et al., 2022; 36384290, Liu et al., 2023; 36793426, Ramharter et al., 2021; 33719426, Ketcham et al., 2022; 35833726) or in combination with covalent KRAS G12C inhibitors (Ketcham et al., 2022; 35833726, Haling et al., 2022; AACR Abstract ND02, Savarese et al., 2021; AACR Abstract 1271) and MEK inhibitors (Haling et al., 2022; AACR Abstract ND02, Norgard et al., 2022 AACR Tumor Immunology and Immunotherapy Abstract B23, Hofmann et al., 2022; AACR Abstract 3255, Plangger et al., 2022; 36048281, Ma et al., 2022; 36139627).", "Include": "true", "ClinicalTrialNote": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05669482", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}, {"nctId": "NCT03825289", "Include": "true"}, {"nctId": "NCT04132505", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of bTMB levels in pancreatic carcinoma are limited (PubMed, Jul 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "F414fs*7", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "17.4", "isEquivocal": "false", "name": "F414fs*7"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, COSMIC, PubMed, Feb 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2023). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KMT2D (MLL2)", "Include": "true", "Alterations": {"Alteration": {"Name": "E4969fs*26", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.92", "isEquivocal": "false", "name": "E4969fs*26"}}, "Interpretation": "MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (cBio_Zehir et al., 2017; 28481359), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "F270C", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.91", "isEquivocal": "false", "name": "F270C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 33_75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, Morton et al., 2010; 20018721, Scarpa et al., 1993; 8494051, Luo et al., 2013; 22782330). TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis (Iacobuzio_Donahue et al., 2012; 22896692, Macgregor_Das and Iacobuzio_Donahue, 2013; 22806689). Additionally, aberrant expression of p53 has been found in 54_81% of pancreatic ductal adenocarcinoma cases (Oshima et al., 2013; 23470568, Ottenhof et al., 2012; 22351431, Tsiambas et al., 2010; 20414934, Scarpa et al., 1993; 8494051). Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis (Ansari et al., 2011; 21644238, Oshima et al., 2013; 23470568, Grochola et al., 2011; 21404460). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "KRAS", "Alteration": "Q61H", "Title": "Study of Avutometinib (VS_6766) +Defactinib With Gemcitabine and Nab_paclitaxel in Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1/2", "Target": "RAFs, MEK, FAK", "Locations": "Missouri, New York, Pennsylvania", "NCTID": "NCT05669482", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61H", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Massachusetts, New York, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61H", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "Q61H", "Title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Texas", "NCTID": "NCT04132505", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "2", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "3", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "4", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "5", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "6", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "7", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "8", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "9", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "10", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "11", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "12", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "13", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "14", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "15", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "16", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "17", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "18", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "19", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "20", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "21", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "22", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "23", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "24", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "25", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "26", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "27", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "28", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "29", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "30", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "31", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "32", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "33", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "34", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "35", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "36", "ReferenceId": "35240087", "FullCitation": "Zhu X, et al. Lancet Oncol (2022) pmid: 35240087", "Include": "true"}, {"number": "37", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "38", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "39", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "40", "ReferenceId": "31694832", "FullCitation": "Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832", "Include": "true"}, {"number": "41", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "42", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "43", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "44", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "45", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "46", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "47", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "48", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "49", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "50", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "51", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "52", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "53", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "54", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "55", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "56", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "57", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "58", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "59", "ReferenceId": "36173339", "FullCitation": "He H, et al. J Med Chem (2022) pmid: 36173339", "Include": "true"}, {"number": "60", "ReferenceId": "36384290", "FullCitation": "Zhang S, et al. J Med Chem (2022) pmid: 36384290", "Include": "true"}, {"number": "61", "ReferenceId": "36793426", "FullCitation": "Liu M, et al. ACS Med Chem Lett (2023) pmid: 36793426", "Include": "true"}, {"number": "62", "ReferenceId": "33719426", "FullCitation": "Ramharter J, et al. J Med Chem (2021) pmid: 33719426", "Include": "true"}, {"number": "63", "ReferenceId": "35833726", "FullCitation": "Ketcham JM, et al. J Med Chem (2022) pmid: 35833726", "Include": "true"}, {"number": "64", "ReferenceId": "36048281", "FullCitation": "Plangger A, et al. Discov Oncol (2022) pmid: 36048281", "Include": "true"}, {"number": "65", "ReferenceId": "36139627", "FullCitation": "Ma Y, et al. Cancers (Basel) (2022) pmid: 36139627", "Include": "true"}, {"number": "66", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "67", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "68", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "69", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "70", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "71", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "72", "ReferenceId": "20018721", "FullCitation": "Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721", "Include": "true"}, {"number": "73", "ReferenceId": "8494051", "FullCitation": "Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051", "Include": "true"}, {"number": "74", "ReferenceId": "22782330", "FullCitation": "Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330", "Include": "true"}, {"number": "75", "ReferenceId": "22896692", "FullCitation": "Iacobuzio_Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692", "Include": "true"}, {"number": "76", "ReferenceId": "22806689", "FullCitation": "Macgregor_Das AM, et al. J Surg Oncol (2013) pmid: 22806689", "Include": "true"}, {"number": "77", "ReferenceId": "23470568", "FullCitation": "Oshima M, et al. Ann. Surg. (2013) pmid: 23470568", "Include": "true"}, {"number": "78", "ReferenceId": "22351431", "FullCitation": "Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431", "Include": "true"}, {"number": "79", "ReferenceId": "20414934", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 20414934", "Include": "true"}, {"number": "80", "ReferenceId": "21644238", "FullCitation": "Ansari D, et al. Br J Surg (2011) pmid: 21644238", "Include": "true"}, {"number": "81", "ReferenceId": "21404460", "FullCitation": "Grochola LF, et al. Pancreas (2011) pmid: 21404460", "Include": "true"}, {"number": "82", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "83", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "84", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "85", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "86", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "87", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "88", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "89", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "90", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "91", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "92", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "93", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "94", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "95", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "96", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "97", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "98", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "99", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "100", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "101", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "102", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "103", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "104", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "105", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "106", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "107", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "108", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "109", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "110", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "111", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "112", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "113", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "114", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "115", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "116", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "117", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "118", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "119", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "120", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "121", "ReferenceId": "15861382", "FullCitation": "Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382", "Include": "true"}, {"number": "122", "ReferenceId": "25383530", "FullCitation": "Guo X, et al. Nature (2015) pmid: 25383530", "Include": "true"}, {"number": "123", "ReferenceId": "30705090", "FullCitation": "Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090", "Include": "true"}, {"number": "124", "ReferenceId": "29414941", "FullCitation": "Zhang ZM, et al. Nature (2018) pmid: 29414941", "Include": "true"}, {"number": "125", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "126", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "127", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "128", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "129", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "130", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "131", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "132", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "133", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "134", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "135", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "136", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "137", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "138", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "139", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "140", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "141", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "142", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "143", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "144", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "145", "ReferenceId": "36512912", "FullCitation": "Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912", "Include": "true"}, {"number": "146", "ReferenceId": "33811152", "FullCitation": "Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152", "Include": "true"}, {"number": "147", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "148", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "149", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "150", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "151", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "152", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "153", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "154", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "155", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "156", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "157", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "158", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "159", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "160", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "161", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "162", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "163", "ReferenceId": "21447625", "FullCitation": "Vicent GP, et al. Genes Dev. (2011) pmid: 21447625", "Include": "true"}, {"number": "164", "ReferenceId": "21671394", "FullCitation": "Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394", "Include": "true"}, {"number": "165", "ReferenceId": "31128216", "FullCitation": "Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216", "Include": "true"}, {"number": "166", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "167", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "168", "ReferenceId": "28007623", "FullCitation": "Augert A, et al. J Thorac Oncol (2017) pmid: 28007623", "Include": "true"}, {"number": "169", "ReferenceId": "29627316", "FullCitation": "Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316", "Include": "true"}, {"number": "170", "ReferenceId": "29950560", "FullCitation": "Hillman RT, et al. Nat Commun (2018) pmid: 29950560", "Include": "true"}, {"number": "171", "ReferenceId": "29532228", "FullCitation": "Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228", "Include": "true"}, {"number": "172", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "173", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "174", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "175", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "176", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "177", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "178", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "179", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "180", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "181", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "182", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "183", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "184", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "185", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "186", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "187", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "188", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "189", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_05_15 20:29:11", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas adenosquamous carcinoma", "flowcell_analysis": "2000029051", "gender": "female", "pathology_diagnosis": "Pancreatic cancer", "pipeline_version": "v3.22.0", "purity_assessment": "4.4", "specimen": "ORD_1624876_01*US1550561.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1624876_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1550561.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4716", "cds_effect": "184G>A", "depth": "651", "equivocal": "false", "functional_effect": "missense", "gene": "VHL", "percent_reads": "47.16", "position": "chr3:10183715", "protein_effect": "V62M", "status": "unknown", "strand": "+", "transcript": "NM_000551", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.4965", "cds_effect": "2015C>T", "depth": "2159", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "49.65", "position": "chr9:98231268", "protein_effect": "T672M", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0074", "cds_effect": "746delC", "depth": "1485", "equivocal": "false", "functional_effect": "frameshift", "gene": "RET", "percent_reads": "0.74", "position": "chr10:43600519", "protein_effect": "A249fs*6", "status": "unknown", "strand": "+", "transcript": "NM_020975", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0023", "cds_effect": "331G>A", "depth": "5636", "equivocal": "false", "functional_effect": "missense", "gene": "PDCD1LG2", "percent_reads": "0.23", "position": "chr9:5535020", "protein_effect": "D111N", "status": "unknown", "strand": "+", "transcript": "NM_025239", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.5087", "cds_effect": "218A>C", "depth": "2233", "equivocal": "false", "functional_effect": "missense", "gene": "CD79B", "percent_reads": "50.87", "position": "chr17:62007646", "protein_effect": "N73T", "status": "unknown", "strand": "_", "transcript": "NM_000626", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.5316", "cds_effect": "2392C>T", "depth": "1345", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2B", "percent_reads": "53.16", "position": "chr1:204416661", "protein_effect": "P798S", "status": "unknown", "strand": "_", "transcript": "NM_002646", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0096", "cds_effect": "183A>C", "depth": "5968", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "0.96", "position": "chr12:25380275", "protein_effect": "Q61H", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.174", "cds_effect": "1238_1239insG", "depth": "1678", "equivocal": "false", "functional_effect": "frameshift", "gene": "DNMT3A", "percent_reads": "17.4", "position": "chr2:25469529", "protein_effect": "F414fs*7", "status": "likely", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.5138", "cds_effect": "528C>A", "depth": "8492", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "51.38", "position": "chrX:66765516", "protein_effect": "S176R", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0067", "cds_effect": "116C>T", "depth": "3859", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "0.67", "position": "chr7:55210006", "protein_effect": "T39M", "status": "unknown", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0092", "cds_effect": "14904delT", "depth": "2707", "equivocal": "false", "functional_effect": "frameshift", "gene": "MLL2", "percent_reads": "0.92", "position": "chr12:49420844", "protein_effect": "E4969fs*26", "status": "likely", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0015", "cds_effect": "743G>A", "depth": "5356", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "0.15", "position": "chr4:1803565", "protein_effect": "R248H", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.001", "cds_effect": "7466C>T", "depth": "5216", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "0.1", "position": "chr11:108201099", "protein_effect": "S2489F", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0091", "cds_effect": "809T>G", "depth": "7003", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "0.91", "position": "chr17:7577129", "protein_effect": "F270C", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.0029", "cds_effect": "1210A>G", "depth": "2055", "equivocal": "false", "functional_effect": "missense", "gene": "CUL4A", "percent_reads": "0.29", "position": "chr13:113899531", "protein_effect": "I404V", "status": "unknown", "strand": "+", "transcript": "NM_003589", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"allele_fraction": "0.4786", "cds_effect": "608C>T", "depth": "1427", "equivocal": "false", "functional_effect": "missense", "gene": "MEF2B", "percent_reads": "47.86", "position": "chr19:19257618", "protein_effect": "P203L", "status": "unknown", "strand": "_", "transcript": "NM_001145785", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HHV_8", "reads_per_million": "26", "status": "unknown", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"organism": "HPV_16", "reads_per_million": "54", "status": "unknown", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}, {"organism": "HHV_4", "reads_per_million": "59", "status": "unknown", "dna_evidence": {"sample": "SQ_US1550561.01_1"}}]}}}}}